OKYO Pharma Limited
OKYOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, OKYO Pharma Limited focuses on Biotechnology services and products. OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. The company carries a $75.6M market cap, placing it firmly in the micro-cap category. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis.
Market Cap
$75.6M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-2.18
EPS (TTM)
$-0.26
EPS (Fwd)
$-0.66
ROE
-263.8%
ROA
-43.1%
Cash
$20.6M
Total Debt
$0
Free CF
-$4.4M
52W Change
-47.6%
Annual Financials
Cash vs Debt
Where OKYO stands vs its 150-day and 200-day moving averages
As of the July 9, 2026 close, OKYO finished 7.26% below its 150-day moving average ($1.79) and 13.09% below its 200-day moving average ($1.91). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is OKYO overbought or oversold?
At the July 9, 2026 close, OKYO's RSI(14) was 64.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
OKYO Pharma Limited reports $20.6M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$4.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -263.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing OKYO.